Short Interest in Bruker Co. (NASDAQ:BRKR) Decreases By 12.2%

Bruker Co. (NASDAQ:BRKR) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 3,810,000 shares, a drop of 12.2% from the October 15th total of 4,340,000 shares. Approximately 3.7% of the shares of the stock are sold short. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 3.3 days.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. First Horizon Advisors Inc. increased its position in Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares during the period. Covestor Ltd grew its position in Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after buying an additional 210 shares in the last quarter. True Wealth Design LLC raised its holdings in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 510 shares in the last quarter. UMB Bank n.a. lifted its position in Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares during the period. Finally, Gordian Capital Singapore Pte Ltd acquired a new stake in Bruker during the second quarter worth $52,000. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Down 4.1 %

NASDAQ BRKR traded down $2.08 during trading on Monday, reaching $49.22. 1,069,799 shares of the company’s stock were exchanged, compared to its average volume of 1,079,670. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker has a fifty-two week low of $49.05 and a fifty-two week high of $94.86. The company’s fifty day simple moving average is $62.60 and its 200-day simple moving average is $65.21. The firm has a market capitalization of $7.46 billion, a PE ratio of 24.66, a P/E/G ratio of 2.46 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. During the same period in the previous year, the firm posted $0.74 earnings per share. The business’s revenue for the quarter was up 16.4% on a year-over-year basis. Sell-side analysts predict that Bruker will post 2.4 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on BRKR. Barclays cut their target price on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Citigroup dropped their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Wells Fargo & Company reduced their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Finally, TD Cowen dropped their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.